Market Data 
Markets
Replies to post #766946 on NorthWest Biotherapeutics Inc (NWBO)
Every year, the resources that NHS England receives are allocated to the services and treatments provided for patients. NHS England decides the treatments it will invest in on an annual basis through a prioritisation process (twice a year for specialised commissioning treatments and services). As far as possible, funding is shared fairly and appropriately, considering the competing demands on NHS England's budget. When a new service or a change to a service is proposed, it
would not be fair for that to bypass the prioritisation process and be funded without comparing it to other possibilities for investment. Because of this, NHS England’s default position is that a new service will not be routinely commissioned until it has been assessed through the full service development process. Very occasionally a development is of such importance that there should be no delay in its introduction. If this is the case it is considered under the urgent development process - www.england.nhs.uk/commissioning/spec-services/key-docs/#serv-dev.
On an individual basis, there may be situations where a clinician believes that their patient’s clinical situation is so different to other patients with the same condition that they should have their treatment paid for when other patients would not. In such cases, NHS clinicians can ask NHS England, on behalf of a patient, to fund a treatment which would not usually be provided by NHS England for that patient. This request is called an Individual Funding Request (IFR).
Funding for additional treatments outside the prioritisation process can only be done by reducing the funding that is available for other established treatments.
There is no allocated separate budget to meet the costs of providing treatments agreed through the IFR process. It is because of this that very careful consideration is required before the decision is taken to fund a treatment that is not usually available for an individual.
05/12/25 8:04 AM
I believe NHS will try to stream line DCVAX-l approval process for all types of tumor cancers once they confirmed efficacy of DCVAX-l through rolling review of RWE with IFR means.
What is likely happening here is that NHS has looked at all of DCVax-L's data and concluded that they need to get this treatment to its citizenry NOW. So, the NHS is using IFR funding to jump-start DCVax-L accessibility. It's as if NHS said to NICE, " DCVax-L is a godsend. We need to make this available now. I know you have to go through your process before our citizenry can have full access to DCVax-L but we are going to place DCVax-L on the HCD list to make this available NOW while you work through your process." Were you aware that NHS added significant additional funding to cancer treatment in 2024?
AI
